Oxford Bio Abandons Prostate Cancer Vaccine Study

Britain’s Oxford BioMedica said it was closing a mid-stage clinical trial of its cancer vaccine TroVax in U.S. patients with prostate cancer, dealing a further blow to the troubled product.
Reuters